{"id":28490,"date":"2022-11-29T09:00:00","date_gmt":"2022-11-29T09:00:00","guid":{"rendered":"http:\/\/6e8f49ea399f7da37b58f1a72956c5e8"},"modified":"2024-11-03T15:13:11","modified_gmt":"2024-11-03T15:13:11","slug":"esmo-immuno-oncology-congress-2022-7-9-december-geneva-switzerland","status":"publish","type":"post","link":"https:\/\/ogkologos.com\/en\/esmo-immuno-oncology-congress-2022-7-9-december-geneva-switzerland\/","title":{"rendered":"ESMO Immuno-Oncology Congress 2022, 7-9 December, Geneva, Switzerland"},"content":{"rendered":"<p>LUGANO, Switzerland&nbsp;\u2013 The <a href=\"https:\/\/www.esmo.org\/meeting-calendar\/esmo-immuno-oncology-congress-2022\" class>ESMO Immuno-Oncology Congress 2022,<\/a> an annual congress dedicated to the presentation and discussion of the latest scientific developments in this fast-moving field, will be held in person in Geneva, Switzerland, and virtually between 7-9 December. The <a href=\"https:\/\/cslide.ctimeetingtech.com\/immuno22hybrid\/attendee\/confcal\/session\/calendar?\" target=\"_blank\" rel=\"noopener noreferrer\" class>Scientific Programme<\/a> aims to highlight the state of the art in immuno-oncology and trigger discussions on the novelties to determine how progress in this field can be accelerated.&nbsp;<\/p>\n<h4>Programme highlights<\/h4>\n<ul>\n<li>The landscape of&nbsp;Immune Checkpoint Inhibitors (ICI): new insights on the efficacy and side-effects of treatment across multiple tumor types<br \/>Related content:<a href=\"https:\/\/cslide.ctimeetingtech.com\/immuno22hybrid\/attendee\/confcal\/session\/calendar?q=lba1\" target=\"_blank\" rel=\"noopener noreferrer\" class>Mini Oral session 2- LBA 1 and 2MO<\/a>, Abstracts 237P, 64P and 4P<\/li>\n<li>How biomarkers can predict response to treatment and accelerate personalisation of immunotherapy<br \/>Related content: <a href=\"https:\/\/cslide.ctimeetingtech.com\/immuno22hybrid\/attendee\/confcal\/session\/calendar?q=lba1\" target=\"_blank\" rel=\"noopener noreferrer\" class>Mini Oral session 2- 3MO<\/a>, Abstracts 22P and 4P<\/li>\n<li>New insights on the safety and efficacy of combination therapy<br \/>Related content: <a href=\"https:\/\/cslide.ctimeetingtech.com\/immuno22hybrid\/attendee\/confcal\/session\/calendar?q=lba1\" target=\"_blank\" rel=\"noopener noreferrer\" class>Mini Oral session 2- 200MO<\/a>, Abstracts 102P, 175P and 73P<\/li>\n<li>Hyperprogressive disease and its potential role in predicting survival<br \/>Related content: Abstracts 94P and 25P<\/li>\n<li>Therapeutic cancer vaccines: how (and whether) can they reach their full potential?<br \/>Related content: <a href=\"https:\/\/cslide.ctimeetingtech.com\/immuno22hybrid\/attendee\/confcal\/session\/calendar?q=lba1\" target=\"_blank\" rel=\"noopener noreferrer\" class>Controversy session<\/a> on 7 December 14:05 CET and abstract 182P<\/li>\n<\/ul>\n<h4>Keynote lectures<\/h4>\n<p>Award Keynote lecture \u201cOvercoming resistance to immunotherapy: Targeting innate immune cells\u201d by Nina Bhardwaj, Wednesday 7 December 2022, 13:15 CET<\/p>\n<p>The results of more than 240 studies from various parts of the world will be presented, and published online as a supplement to <em>ESMO IOTECH<\/em>. The abstract titles can be viewed <a href=\"https:\/\/cslide.ctimeetingtech.com\/immuno2022\/attendee\/confcal\/session\/calendar?\" target=\"_blank\" rel=\"noopener noreferrer\" class>online<\/a>.<\/p>\n<h4>Media registration<\/h4>\n<p>ESMO welcomes media interested in obtaining information and reporting on cancer issues. Registration is free to bona fide journalists on presentation of a letter of assignment and a valid press card. Media representatives are required to observe and abide by the <a href=\"https:\/\/www.esmo.org\/newsroom\/esmo-media-policy\" class>Media Policy<\/a>. To apply for media accreditation, please fill out the form available <a href=\"https:\/\/esmo.formstack.com\/forms\/media_registration_form_esmo_io_2022\" target=\"_blank\" rel=\"noopener noreferrer\" class>here<\/a>.<\/p>\n<h4>Further information<\/h4>\n<p>ESMO Press Office <br \/><a href=\"mailto:press@esmo.org\" target=\"_blank\" rel=\"noopener noreferrer\" class>press@esmo.org<\/a><\/p>\n<h4>Notes to Editors<\/h4>\n<p>Please make sure to use the official name of the meeting in your reports:<strong>&nbsp;ESMO Immuno-Oncology Congress 2022<\/strong> and the official congress hashtag: <strong>#<\/strong><strong>ESMOImmuno22<\/strong><\/p>\n<p>Follow the conversation on&nbsp;<a href=\"https:\/\/twitter.com\/myesmo\" target=\"_blank\" rel=\"noopener noreferrer\" class=\"external-link\">Twitter<\/a>,&nbsp;<a href=\"https:\/\/www.linkedin.com\/company\/european-society-for-medical-oncology\/\" target=\"_blank\" rel=\"noopener noreferrer\" class=\"external-link\">LinkedIn,<\/a>&nbsp;<a href=\"https:\/\/www.instagram.com\/esmo_eur_oncology\/\" target=\"_blank\" rel=\"noopener noreferrer\" class=\"external-link\">Instagram<\/a>,&nbsp;<a href=\"https:\/\/www.facebook.com\/esmo.org\/\" target=\"_blank\" rel=\"noopener noreferrer\" class=\"external-link\">Facebook<\/a><\/p>\n<p><a href=\"https:\/\/www.esmo.org\/newsroom\/press-releases\/esmo-immuno-oncology-congress-2022-7-9-december-geneva-switzerland\">Source<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>LUGANO, Switzerland&nbsp;\u2013 The ESMO Immuno-Oncology Congress 2022, an annual congress dedicated to the presentation and discussion of the latest scientific developments in this fast-moving field, will be held in person in Geneva, Switzerland, and virtually between 7-9 December. The Scientific Programme aims to highlight the state of the art in immuno-oncology and trigger discussions on [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"footnotes":""},"categories":[5137],"tags":[],"class_list":["post-28490","post","type-post","status-publish","format-standard","hentry","category-world-news"],"_links":{"self":[{"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/posts\/28490","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/comments?post=28490"}],"version-history":[{"count":1,"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/posts\/28490\/revisions"}],"predecessor-version":[{"id":44792,"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/posts\/28490\/revisions\/44792"}],"wp:attachment":[{"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/media?parent=28490"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/categories?post=28490"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/tags?post=28490"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}